A new ranibizumab injection offers hope for patients with wet age-related macular degeneration, according to a presentation at Hawaiian Eye 2022. It was great to catch up with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA), who talked to us about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections.
The abstract entitled Update on Emerging Wet AMD Therapies was presented at Hawaiian Eye 2022, 15–21 January 2022.
Questions
- Could you tell us a little about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections? (00:15)
- What is the likely role of faricimab in the treatment paradigm for wet age-related macular degeneration? (02:15)
Speaker Disclosure: Carl Regillo has received speakers’ fees from Genentech, Allergan, Annexon, Novartis, Apellis, Iveric, NGM, Adverum, Regenxbio, Regeneron, Opthea, Thea.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of Hawaiian Eye 2022.
